Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.
Uses AI and lab automation to discover antibodies for pharma partners and its own drug pipeline.
Earns research fees, milestones and royalties from partners that use its platform to find antibodies, and invests in its own drug candidates. Its income spiked in 2021 on royalties from the COVID antibody it helped find for Lilly, and has since come from smaller partner programmes while it builds its own pipeline.
In one line: A discovery-stage biotech, like Moderna but for antibodies rather than mRNA.
Moat: narrow (data, IP / patents, process know-how). Large proprietary antibody discovery database and high-throughput screening platform.
Headquarters: Vancouver, Canada · Founded: 2012 · Employees: 562
Size AbCellera Biologics (ABCL) is a United States Health Care company (Biotechnology) with a market value of $3.60B, the 1407th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.02 on 18 Nov 2026.
Performance Over six months the shares gained 141.1%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 92.1% over the last twelve months (peer median +8.3%); the operating margin is -298.0% (peer median -0.7%).
Valuation It trades at 43.4× enterprise value to sales against a peer median of 8.7× (5th most expensive of 16).
Capital Return on invested capital runs 52.0 points below its cost of capital (12.8% WACC).
Backlog Backlog (remaining performance obligations) was $56.0M at 30 Jun 2026. Backlog detail →
Short interest Short interest is 9.0% of the free float (30 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $67.9M | $75.1M | $28.8M | $38.0M | $485M |
| Revenue growth | — | +161% | -24% | -92% | — |
| Gross profit | $33.9M | $46.3M | -$68.2M | $7.13M | n/a |
| EBITDA | -$168M | -$188M | -$218M | -$206M | $316M |
| Net income | -$148M | -$146M | -$163M | -$146M | $159M |
| Free cash flow | -$31.3M | -$174M | -$187M | -$121M | $207M |
| Capital expenditure | $16.9M | $42.8M | $78.4M | $77.5M | $72.7M |
| Total debt | $134M | $143M | $65.4M | $77.4M | $82.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| AbCellera Biologics ABCL | $3.60B | +141% | +92% | -298% | 43.4× | n/a |
| Twist Bioscience TWST | $7.93B | +117% | +22% | -29% | 16.2× | n/a |
| Absci ABSI | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a |
| OmniAb OABI | $741M | +97% | +91% | -116% | 17.3× | 60.6% |
| Evotec EVT.DE | $532M | -46% | -5% | -15% | 0.8× | n/a |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 4.7× | 25.6% |
| Genscript Biotech 1548.HK | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABCL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.9% | -5.1% | 11th highest of 21 |
| 6-month return | +141.1% | -2.0% | 3rd highest of 21 |
| Distance from 52-week high | -26.6% | -32.6% | 7th highest of 21 |
| Revenue growth (TTM) | +92.1% | +8.3% | 2nd highest of 16 |
| Operating margin | -298.0% | -0.7% | 5th lowest of 16 |
| EV / Sales | 43.4× | 8.7× | 5th most expensive of 16 |
| ROIC minus cost of capital | -52.0 pp | -6.2 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 11.8× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
AbCellera Biologics reported $56.0M of remaining performance obligations at 30 Jun 2026.